The DOI matches its Crossref record; 72 of the 72 references it cites were found in a registry or an index; 39 of the 66 sources its claims cite were checked for support.
Spatial pharmacology of anti-cancer immunomodulators: a comprehensive review
Open accessAbstract
The field of spatial pharmacology has emerged as a critical framework for understanding the complex interactions between anti-cancer immunomodulators, tumor cells, and the tumor microenvironment (TME) at single-cell resolution. This review synthesizes the theoretical foundations, historical evolution, clinical applications, diagnostic techniques, therapeutic strategies, and future directions of spatial pharmacology in cancer immunotherapy. By integrating single-cell analysis, signaling dynamics, and multimodal approaches, spatial pharmacology addresses the limitations of traditional "one-size-fits-all" therapies by accounting for intratumoral heterogeneity, drug target accessibility, and immune cell spatial organization. Key advancements include single-cell RNA sequencing (scRNA-seq) for mapping drug target pathway activation, imaging techniques for visualizing signaling dynamics, and multimodal diagnostics for personalized treatment design. Clinical applications range from optimizing combinatorial regimens in metastatic renal cell carcinoma to predicting immunotherapy response in triple-negative breast cancer. Despite challenges such as overcoming drug resistance and enhancing target accessibility, emerging technologies like spatial transcriptomics and artificial intelligence (AI)-driven multi-omics integration promise to revolutionize precision oncology. This review highlights how spatial pharmacology is transforming cancer immunotherapy by enabling tailored interventions that account for the spatial and temporal complexity of tumor-immune interactions.
Overview
CoChat Summary
TL;DR
This review synthesizes spatial pharmacology for anti-cancer immunomodulators, integrating single-cell analysis, imaging, spatial transcriptomics, and AI to map drug-target engagement and immune signaling in the tumor microenvironment. It argues that intratumoral spatial and single-cell heterogeneity drives variable drug accessibility, resistance, and immunotherapy response, motivating multimodal, spatially resolved precision strategies.
Key findings
- Single-cell and spatial heterogeneity affects every step of drug action: BTK and PARP inhibitors show variable target occupancy despite high average engagement; doxorubicin-chromatin binding varies between metastases and regions; intranuclear drug diffusion is three orders of magnitude slower than in vitro.
- Target expression and accessibility are heterogeneous: glioblastoma integrin αvβ3 surface density ranges from 0 to 1.6 molecules per μm² and correlates with integrin-inhibitor sensitivity; renal cell carcinoma markers SPOCK1, PTGIS, and REG1A vary across subpopulations and pathological types; TRIPODD shows drug target availability is not always correlated with protein expression.
- Clinical and translational examples include scRNA-seq-guided combinatorial regimens in metastatic renal cell carcinoma that improved efficacy in patient-derived xenograft models; entinostat in relapsed/refractory Hodgkin lymphoma with a 24% disease control rate and tumor reduction in 58% of evaluable patients; DBCSMOTE predicting warfarin dose within 20% in 47.8% of cases; and rituximab binding varying with up to 1200 radionuclides per cell.
- Therapeutic strategies include co-targeting pathways (e.g., AURK/CDK/EGFR in glioblastoma; RAF/MEK/ERK in BRAF V600E-mutant cancer, effective in 11 of 11 patient-derived xenografts) and enhancing delivery (iRGD, T-DM1, losartan, pH/redox-responsive nanoparticles); future directions include spatial transcriptomics, AI-driven multi-omics, neoantigen vaccines, and biomarkers such as spatial immune infiltration and TCR clonality.
Methods
- Design: comprehensive narrative review of spatial pharmacology in cancer immunotherapy, covering theoretical foundations, historical evolution, clinical practice, diagnostic techniques, therapeutic strategies, and future directions.
- Evidence base: synthesizes cited preclinical and clinical studies using scRNA-seq, scATAC-seq, mass spectrometry imaging, fluorescence imaging, spatial transcriptomics, AI/multimodal models, and organoid or microfluidic models.
- Analysis: narrative synthesis with conceptual figures, including a hierarchical framework in Figure 2; no systematic search strategy, inclusion criteria, or quantitative meta-analysis is described.
Limitations
- The review does not state formal limitations of its own methodology; it states field challenges including drug resistance, target accessibility, and limitations of current biomarkers such as PD-L1, tumor mutation burden, and microsatellite instability.
- Evident from the text: as a narrative review, it lacks systematic search and selection methods and quantitative synthesis, so conclusions depend on the cited literature.
- Evident from the text: examples include non-oncologic or non-immunomodulator contexts (e.g., retinal vein occlusion, atherosclerosis, neuropsychiatric signaling, cardiac repair), which may limit direct generalizability to anti-cancer immunomodulation.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
38 Valid · 1 Not valid · 28 Not checked · 11 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“For example, glioblastoma cells exhibit discrete distribution of integrin αvβ3, a key drug target, with surface density ranging from 0 to 1.6 molecules per μm2 (Wang et al., 2019).”
§ Spatial pharmacology of anti-cancer immunomodulators: a comprehensive review > Spatial pharmacology of anti-cancer immunomodulators: theoretical foundations > Single-cell heterogeneity in drug target accessibility
What the sources say
- Supportedcites Wang et al., 2019 source
The Introduction describes the receptors’ distribution as discrete, and the quantitative-analysis section reports surface densities of approximately 1.6 and 1.2 molecules per μm² in two glioblastoma cell lines, with none detected in a third. These findings support the stated range of 0 to 1.6 molecules per μm²; the paper also studies integrin αvβ3 as a drug target. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“For example, RLM revealed marked differences in rituximab binding between single cells, with some cells accumulating up to 1200 radionuclides per cell (Natarajan et al., 2015).”
§ Spatial pharmacology of anti-cancer immunomodulators: a comprehensive review > Spatial pharmacology of anti-cancer immunomodulators: theoretical foundations > Multimodal approaches in spatial pharmacology
What the sources say
- Supportedcites Natarajan et al., 2015 source
The Results report that RLM measured cell-to-cell heterogeneity in [64Cu]rituximab binding: values ranged from background to approximately 1200 64Cu atoms per cell. This directly supports the citing sentence. (LLM, conf=0.95)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The PD-1/PD-L1 pathway is another critical signaling axis in cancer immunotherapy, where cancer cells upregulate PD-L1 to engage PD-1 on T cells, inhibiting their cytotoxic function (Parvez et al., 2023).”
§ Spatial pharmacology of anti-cancer immunomodulators: a comprehensive review > Spatial pharmacology of anti-cancer immunomodulators: theoretical foundations > Signaling dynamics in cancer immunotherapy
What the sources say
- Supportedcites Parvez et al., 2023 source
The “PD-L1 and PD-L2” section says PD-L1 is typically increased in cancer cells and can be upregulated on tumor cells. The “PD-1: PD-L1 signaling” section says PD-1–PD-L1 binding reduces T-cell cytotoxic activity. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“mclSTExp integrates image features with spatial context via a Transformer encoder, achieving superior performance in predicting highly variable genes in breast cancer and skin squamous cell carcinoma datasets (Min et al., 2024).”
§ Spatial pharmacology of anti-cancer immunomodulators: a comprehensive review > Spatial pharmacology of anti-cancer immunomodulators: theoretical foundations > Multimodal approaches in spatial pharmacology
What the sources say
- Partly supportedcites Min et al., 2024 sourceExperimental — accuracy not yet measured
The Abstract reports superior prediction performance for highly variable genes evaluated in two breast cancer datasets and a skin squamous cell carcinoma dataset. The Materials and methods overview distinguishes the mechanisms: the Transformer combines spot features with positional information, while contrastive learning incorporates the image features. The claim is therefore supported on the evaluation and overall integration, but not on its attribution of image–spatial fusion to the Transformer encoder alone. (LLM, conf=0.86)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The Multi-view Contrastive Graph Autoencoder (MCGAE) framework uses deep learning to combine gene expression and spatial adjacency matrices for generating unified embeddings, exceeding present methods in spatial domain identification and noise reduction (Yang et al., 2024).”
§ Spatial pharmacology of anti-cancer immunomodulators: a comprehensive review > Spatial pharmacology of anti-cancer immunomodulators: theoretical foundations > Multimodal approaches in spatial pharmacology
What the sources say
- Supportedcites Yang et al., 2024 source
The Methods (Overview of multi-view contrastive graph autoencoder approach; page unavailable) describe combining gene-expression and spatial views through graph networks and attention to produce a final representation. The Discussion (Key Points; page unavailable) says MCGAE improves spatial domain detection and data denoising, outperforming traditional methods. (LLM, conf=0.91)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
40 more claims · 22 with their cited sources checked
Create a free account to see all 78 claims and every source verdict.
- It may state two separate claims as one. 28
- Probably not a substantial claim. 6
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Spatial pharmacology of anti-cancer immunomodulators: a comprehensive review > Current clinical practices in anti-cancer immunomodulation > Single-cell heterogeneity in drug response
“Similarly, in breast cancer, patient-derived organoids recapitulated the heterogeneity of the original tumor, with different subpopulations showing varying responses to oxaliplatin (Chen et al., 2018).”
§ Spatial pharmacology of anti-cancer immunomodulators: a comprehensive review > References
“Single-cell transcriptomics reveals heterogeneity and drug response of human colorectal cancer organoids.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Spatial pharmacology of anti-cancer immunomodulators: a comprehensive review > Therapeutic strategies and challenges > Enhancing drug target accessibility
“Figure 3 offers a comprehensive visual summary of these multifaceted heterogeneities and the associated analytical methodologies, highlighting the fundamental challenges and technological advancements in the field of single-cell cancer pharmacology.”
§ Spatial pharmacology of anti-cancer immunomodulators: a comprehensive review > Therapeutic strategies and challenges > Enhancing drug target accessibility
“FIGURE 3 Representative strategies for enhancing drug target accessibility in cancer therapy. This three-panel schematic depicts distinct approaches to break tumor delivery barriers, with gradient heatmaps below each panel quantifying delivery performance.”
Citations
Cites
An introduction to chimeric antigen receptor (CAR) T‐cell immunotherapy for human cancer
Feins, S., Kong, W., Williams, E. F., Milone, M. C., & Fraietta, J. A. (2019) · American Journal of Hematology · doi:10.1002/ajh.25418 · Cited by 614 · cited 5×
“To address these challenges, researchers are engineering CAR-T cells to express cytokines or checkpoint inhibitors, enhancing their ability to penetrate and survive in the TME (Feins et al., 2019).”
InfluentialArtificial intelligence-based multi-omics analysis fuels cancer precision medicine
He, X., Liu, X., Zuo, F., Shi, H., & Jing, J. (2023) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.12.009 · Cited by 445 · cited 1×
“AI-driven analysis of single-cell and spatial data is also an emerging trend, with deep learning models being used to identify cell types, predict drug response, and infer gene regulatory networks (He et al., 2023).”
Multiclonal Invasion in Breast Tumors Identified by Topographic Single Cell Sequencing
Casasent, A. K., Schalck, A., Gao, R., Sei, E., Long, A., Pangburn, W., Casasent, T., Meric-Bernstam, F., Edgerton, M. E., & Navin, N. E. (2018) · Cell · doi:10.1016/j.cell.2017.12.007 · Cited by 411 · cited 1×
“Additionally, single-cell sequencing has been used to track the evolution of drug resistance, revealing that polyclonal invasion occurs in breast tumors, with multiple clones escaping the ducts and establishing invasive carcinomas (Casasent et al., 2018).”
Monoclonal antibodies targeting CD 38 in hematological malignancies and beyond
van de Donk, N. W. C. J., Janmaat, M. L., Mutis, T., Lammerts van Bueren, J. J., Ahmadi, T., Sasser, A. K., Lokhorst, H. M., & Parren, P. W. H. I. (2016) · Immunological Reviews · doi:10.1111/imr.12389 · Cited by 353
Integrative Methods and Practical Challenges for Single-Cell Multi-omics
Ma, A., McDermaid, A., Xu, J., Chang, Y., & Ma, Q. (2020) · Trends in Biotechnology · doi:10.1016/j.tibtech.2020.02.013 · Cited by 273
PD-1 and PD-L1: architects of immune symphony and immunotherapy breakthroughs in cancer treatment
Parvez, A., Choudhary, F., Mudgal, P., Khan, R., Qureshi, K. A., Farooqi, H., & Aspatwar, A. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1296341 · Cited by 216 · cited 4×
“The PD-1/PD-L1 pathway is a major target, with inhibitors such as pembrolizumab and nivolumab blocking the interaction between PD-1 on T cells and PD-L1 on cancer cells (Parvez et al., 2023).”
InfluentialKim, K.-T., Lee, H. W., Lee, H.-O., Song, H. J., Jeong, D. E., Shin, S., Kim, H., Shin, Y., Nam, D.-H., Jeong, B. C., et al. (2016) · Genome Biology · doi:10.1186/s13059-016-0945-9 · Cited by 198 · cited 5×
“xenograft models (Kim et al., 2016).”
InfluentialAn approach to suppress the evolution of resistance in BRAFV600E-mutant cancer
Xue, Y., Martelotto, L., Baslan, T., Vides, A., Solomon, M., Mai, T. T., Chaudhary, N., Riely, G. J., Li, B. T., Scott, K., et al. (2017) · Nature Medicine · doi:10.1038/nm.4369 · Cited by 174
Su, C., Lv, Y., Lu, W., Yu, Z., Ye, Y., Guo, B., Liu, D., Yan, H., Li, T., Zhang, Q., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.719564 · Cited by 132 · cited 2×
“Similarly, single-cell analysis of renal cell carcinoma identified novel tumor-specific markers such as SPOCK1, PTGIS, and REG1A, which vary in expression across cell subpopulations and pathological types (Su et al., 2021).”
A visual–omics foundation model to bridge histopathology with spatial transcriptomics
Chen, W., Zhang, P., Tran, T. N., Xiao, Y., Li, S., Shah, V. V., Cheng, H., Brannan, K. W., Youker, K., Lai, L., et al. (2025) · Nature Methods · doi:10.1038/s41592-025-02707-1 · Cited by 118
Self-citation
Cited by
Lai, S., & Shanshan, L. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1952445
Metadata
- Authors
- Chen, S., Tu, L., & Chen, Q.
- Affiliations
- Minxi Vocational & Technical College (CN)
- Xiamen Medical College (CN)
- Corresponding author
- Chen, Quanhua
- Venue
- Frontiers in Pharmacology
- Publisher
- Frontiers Media SA
- Published
- 2026-08-12
- Volume
- 17
- Pages
- 1898418-1898418
- ISSN
- 1663-9812 (ISSN-L)
- PMC
- PMC13543664
- OpenAlex
- W7202254797
- Cited by
- 1
- References
- 72
- Citations by year
- 2026: 1
- FWCI
- 0.92
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Frontiers in Pharmacology (publishedVersion, cc-by)
- PubMed (publishedVersion)
- PubMed Central (publishedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Single-cell and spatial transcriptomics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- tumor microenvironment, cancer immunotherapy, intratumoral heterogeneity, single-cell RNA sequencing, spatial transcriptomics, multimodal diagnostics, precision oncology, drug resistance, renal cell carcinoma, triple-negative breast cancer, immunotherapy response prediction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Spatial pharmacology of anti-cancer immunomodulators: a comprehensive review. https://app.cochat.ai/papers/10.3389/fphar.2026.1898418
- The paper
- Chen, S., Tu, L., & Chen, Q. (2026). Spatial pharmacology of anti-cancer immunomodulators: a comprehensive review. Frontiers in Pharmacology. https://doi.org/10.3389/fphar.2026.1898418
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.